CONMED Q4 2024 sales $345.9M (+5.8% YoY), adjusted EPS $1.34; FY25 guidance issued

CONMED Corp

2024-FY EPS reported $4.25 revenue$1,307,015,000

Q4 GAAP diluted EPS $1.08 (vs $1.05 YoY); adjusted diluted EPS $1.34 (+26.4%).
Full-year 2024 sales $1,307.0M (+5.0% reported); adjusted EPS $4.17 vs $3.45 in 2023.
Q4 single-use product sales +9.6% YoY; capital product sales declined 12.7%.
FY2025 guidance: revenue $1.344-1.372B (4-6% constant currency growth); adjusted EPS $4.25-4.40.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.